This short guide provides advice to healthcare professionals on the management of patients with advanced Parkinson’s disease who have started LECIGON® therapy.
The information presented in these slides is provided as part of additional Risk Minimisation Program for LECIGON® targeted to minimise:
Gastrointestinal (GI) events
Device-related risks
Procedure-related risks associated with the Levodopa–carbidopa–entacapone intestinal gel system
Important Additional Risk Minimisation Information for Healthcare Professionals Training, PEG-J Placement, Aftercare and Minimisation of Procedure Complications
You are trying to reach document intended for healthcare professionals only.
Are you a healthcare professional?
Britannia Pharmaceuticals Limited
Address
200 Longwater Avenue, Green Park, Reading, Berkshire, RG2 6GP, UK